Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021	Dec 31, 2020
Net Income	-170.34	-141.2	-122.53	-89.62	-38.05	-15.88
Depreciation & Amortization	1.64	1.33	0.99	0.3	0.07	-
Stock-Based Compensation	34.71	28.99	18.79	8.19	1.49	0.57
Other Adjustments	-10.87	-23.28	-16.86	-5.32	0.27	0.08
Changes in Accounts Payable	-0.89	4.77	3.31	-0.86	1.9	1.02
Changes in Accrued Expenses	22.37	21.51	7.72	12.16	3.41	0.8
Changes in Other Operating Activities	78.66	-114.32	-8.06	-4.34	-1.25	-0.88
Operating Cash Flow	-154.74	-222.2	-116.64	-79.49	-32.16	-14.28
Capital Expenditures	-4.48	-3.61	-1.29	-2.17	-1.21	-0.02
Purchases of Investments	-1,079	-547.38	-702.52	-417.36	-4.21	-21.13
Proceeds from Sale of Investments	631.79	630.54	344.9	151.18	23.28	-
Other Investing Activities	-	10.25	-	-	-	-
Investing Cash Flow	-441.18	89.8	-358.91	-268.34	17.86	-21.15
Issuance of Common Stock	5.11	765.15	517.06	473.1	0.01	-
Repurchase of Common Stock	-3.04	-0.62	-	-	-	-
Net Common Stock Issued (Repurchased)	2.08	764.54	517.06	473.1	0.01	-
Issuance of Preferred Stock	-	-	-	-	103.36	25.84
Net Preferred Stock Issued (Repurchased)	-	-	-	-	103.36	25.84
Other Financing Activities	-2.06	-2.02	-1.8	-21.57	-0.12	-
Financing Cash Flow	759.97	762.52	515.26	451.53	103.25	25.84
Net Cash Flow	164.05	630.11	39.72	103.7	88.95	-9.59
Free Cash Flow	-159.22	-225.81	-117.93	-81.66	-33.37	-14.3
Free Cash Flow Per Share	-1.16	-1.27	-0.75	-0.74	-12.30	-3.95
Levered Free Cash Flow	-72.7	-231.52	-119.86	-84.53	-40.84	-15.11
Unlevered Free Cash Flow	-111.59	-266.24	-155.16	-97.41	-34.54	-14.84

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q